Evidence map›Paper›PMID 23911535›Full record

Trial reportJournal of diabetes and its complications

Differences in inpatient glycemic control and response to subcutaneous insulin therapy between medicine and surgery patients with type 2 diabetes.

Dawn Smiley, Guillermo E Umpierrez, Kathie Hermayer, Christopher Newton, Sol Jacobs, Darin E Olson, Amna Khan, Monica Rizzo, Limin Peng, David Reyes and 2 more

Abstract readMulticenter StudyRandomized Controlled Trial
In one paragraph

Trial report in Journal of diabetes and its complications. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
1.0field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 12 citations in OpenAlex.

  1. PROACTIVE PROTOCOL-BASED MANAGEMENT OF HYPERGLYCEMIA AND DIABETES IN COLORECTAL SURGERY PATIENTS.Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists · 2018
    Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 3 institutions in 1 country.

Dawn SmileyDepartment of Medicine, Division of Endocrinology at Emory University, Atlanta, GA, USA. Electronic address: dsmiley@emory.edu.
Guillermo E Umpierrez
Kathie Hermayer
Christopher Newton
Sol Jacobs
Darin E Olson
Amna Khan
Monica Rizzo
Limin Peng
David Reyes
Saumeth Cardona
Vivian Fonseca
Emory University · USTulane Medical Center · USMedical University of South Carolina · US

Funding

Tracking & Evaluation CoreU54GM104940 · NIGMS · LSU PENNINGTON BIOMEDICAL RESEARCH CTR · PI Peter Todd Katzmarzyk · 2012 to 2026
$69.1M
CTSA INFRASTRUCTURE FOR PEDIATRIC RESEARCHUL1RR025008 · NCRR · EMORY UNIVERSITY · PI STEPHENS, DAVID S · 2007 to 2011
$29.0M
Atlanta Clinical and Translational Science Institute (ACTSI) RenewalUL1TR000454 · NCATS · EMORY UNIVERSITY · PI STEPHENS, DAVID S · 2012 to 2016
$25.8M
X LINKED NYSTAGMUS SYNDROME WITH FEATURES OF ALBINISMM01RR000039 · NCRR · EMORY UNIVERSITY · PI VACCARINO, VIOLA · 1985 to 2007
$21.3M
KPDM: Predictive Markers, Underlying Mechanisms, and Treatment OutcomesK08DK083036 · NIDDK · EMORY UNIVERSITY · PI SMILEY, DAWN DIESE · 2009 to 2012
$594k
NCATS NIH HHS UL1 TR000454NCRR NIH HHS M01 RR000039NCRR NIH HHS M01 RR-00039NCRR NIH HHS UL1 RR025008NIDDK NIH HHS K08 DK083036NIGMS NIH HHS U54 GM104940
6 · The paper itself

Abstract

objectiveTo determine differences in inpatient glycemic control and response to two different glargine-based insulin regimens in general medicine and surgery patients with type 2 diabetes (T2D).

methodsThis is a post-hoc analysis of a prospective, multicenter, randomized trial of 298 non-ICU medicine and surgery patients with T2D treated with Basal Bolus regimen with glargine once daily and glulisine before meals and with Basal Plus regimen with glargine once daily and supplemental doses of glulisine before meals for blood glucose (BG)>140mg/dl. Major study outcomes included differences in mean daily BG, frequency of treatment failures (defined as >2 consecutive BG>240mg/dl or a mean daily BG>240mg/dl), and hypoglycemia between the medicine and surgery cohorts.

resultsPatients treated with Basal Bolus or with Basal Plus experienced similar improvement in mean daily BG after 1st day of therapy (p=0.16), number of treatment failures (p=0.11) and hypoglycemic events (p=0.50). Compared to surgery patients (n=130), medicine patients (n=168) had higher admission BG (p=0.01) and HbA1c levels (p<0.01); however, they had similar response to either treatment regimen without differences in mean daily BG after 1st day of therapy (p=0.18), number of treatment failures (p=0.58), daily insulin requirements (p=0.36), or in the frequency of hypoglycemia (p=0.79).

conclusionThe Basal Plus regimen with glargine once daily and correction doses with glulisine before meals resulted in similar glycemic control to basal bolus regimen. We observed no differences in response to either basal insulin regimen between medicine and surgery patients with type 2 diabetes.

Indexed as

InpatientsAgedBlood GlucoseDiabetes Mellitus, Type 2Drug Administration ScheduleFemaleHospitalizationHumansHypoglycemiaHypoglycemic AgentsInjections, SubcutaneousInsulinInsulin GlargineInsulin, Long-ActingMaleMiddle AgedBlood GlucoseHypoglycemic AgentsInsulinInsulin Glargineinsulin glulisineInsulin, Long-ActingBasal insulinGlargineGlulisineHospital hyperglycemiaInpatient hyperglycemiaMedicine and surgery patientsSliding scale insulinType 2 diabetes

Identifiers

PMID23911535
PMCPMC4416966
OpenAlexW2097795752

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.